Letícia Oba Galvão

Letícia Oba Galvão

Auto-generated profile, based on publicly available information

Letícia Oba Galvão

Dermatology Service, Hospital Regional da Asa Norte, Brasília, DF, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
PKPatricia Shu Kurizky
Patricia Shu Kurizky
LGLetícia Oba Galvão
Letícia Oba Galvão
GMGladys Aires Martins
Gladys Aires Martins
The development of immunobiological drugs in recent decades has led to major advances in the treatment of psoriasis and psoriatic arthritis. Drugs such as anti-tumor necrosis factor (anti-TNF) and anti-interleukin 12/23 (anti-IL 12/23), for instance, have proven to be safe and effective alternatives, despite their high production cost.1

8 February 2022 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
LGLetícia Oba Galvão
Letícia Oba Galvão
CRCarmelia Matos Santiago Reis
Carmelia Matos Santiago Reis
NANatália Lima Alves
Natália Lima Alves
EMElisa Scandiuzzi Maciel
Elisa Scandiuzzi Maciel
Varicella is a common viral infection in childhood and usually has a benign evolution. However, the evolution can be severe in immunosuppressed children. Vaccination can prevent its occurrence and especially the development of severe and/or complicated cases. Methotrexate is a systemic therapeutic option for many inflammatory diseases, and its immunosuppressive action exposes its users to a higher susceptibility to infection. The present report describes a case of severe varicella infection in a child immunosuppressed with methotrexate.

2 July 2026 in Dermatology and Therapy
Verified
Journal Article
Open access
LRLuciana A. Ribeiro
Luciana A. Ribeiro
PKPatricia Shu Kurizky
Patricia Shu Kurizky
RSRodrigo R. de Sena
Rodrigo R. de Sena
SFSamia Fares
Samia Fares
GSGabriel B. F. dos Santos
Gabriel B. F. dos Santos
Ciro Martins GomesCiro Martins Gomes
Ciro Martins Gomes
Evaluating psoriasis care in Brazil, a country characterized by its vast geographical expanse, may provide valuable lessons for healthcare systems globally. National research has revealed that individuals receiving biologic treatments in Brazil exhibit lower drug survival rates than individuals from other countries, highlighting challenges that may be applicable elsewhere. The aim of this study was to determine whether distribution problems, poor adherence, and improper storage of immunobiological therapeutics are significant risk factors for reduced drug survival during psoriasis treatment. In this retrospective cohort study, patients diagnosed with psoriasis who were receiving immunobiological therapy were enrolled in a real-world registry. Drug distribution, adherence, and storage problems were evaluated as risk factors. The primary endpoint was drug survival. Relative risk (RR) and Kaplan‒Meier analyses were used to assess associations, and multivariable analysis was performed via accelerated failure time modeling. Among 166 patients, 82 (49.40%) discontinued treatment. Adalimumab was the most frequently administered biologic (n = 77), followed by secukinumab (n = 40), risankizumab (n = 9), guselkumab (n = 8), infliximab (n = 6), etanercept (n = 4), and ustekinumab (n = 19). Bimekizumab, brodalumab, and certolizumab pegol were each used by one patient. Distribution problems increased the risk of treatment interruption (RR = 1.45, 95% confidence interval [CI]: 1.07-1.95). After adjustment, the adverse impact of distribution problems diminished, most likely because of adalimumab's more frequent dosing schedule. Adalimumab use was linked to shorter drug survival (hazard ratio = 1.51, 95% CI: 1.01-2.27). Postinjection management also raised concerns: 22.23% of patients reported disposing of biologic waste in the regular trash. In settings marked by significant stress within the distribution, storage, and administration chains for immunobiologics, distribution problems appear to negatively affect drug survival. The use of therapies with longer dosing intervals or oral medications may help overcome these barriers.

1 March 2022 in Anais Brasileiros de Dermatologia (Versão em Português)
Verified
Journal Article
Open access
LGLetícia Oba Galvão
Letícia Oba Galvão
CRCarmelia Matos Santiago Reis
Carmelia Matos Santiago Reis
NANatália Lima Alves
Natália Lima Alves
EMElisa Scandiuzzi Maciel
Elisa Scandiuzzi Maciel